Differential Outcomes with Empagliflozin and Dapagliflozin in Heart Failure with Mildly Reduced Ejection Fraction
Abstract
Abstrac:
Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure (HF), yet comparative effectiveness between individual agents in heart failure with mildly reduced ejection fraction (HFmrEF) remains limited.
Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network electronic health record database. Adults (≥18 years) with HF and left ventricular ejection fraction (LVEF) 41–49% initiating empagliflozin or dapagliflozin between September 2021 and December 2025 were included. Propensity score matching (1:1) balanced demographics, comorbidities, medications, and laboratory values, yielding 1,466 patients per group. Outcomes were assessed over 1 year after treatment initiation and included all-cause mortality, hospitalization, HF exacerbation, and urinary tract infection (UTI). Risk analyses and Kaplan–Meier survival analyses with hazard ratios (HRs) were performed.
Results: In the matched cohort, empagliflozin was associated with lower all-cause mortality (HR 0.75, 95% CI 0.59–0.96), substantially fewer hospitalizations (HR 0.61, 95% CI 0.55–0.67), and HF exacerbations (HR 0.64, 95% CI 0.57–0.73) compared to dapagliflozin. Rates of UTI were similar between groups (HR 0.81, 95% CI 0.65–1.01).
Conclusions: In this large real-world HFmrEF population, empagliflozin was associated with lower mortality, hospitalization, and HF exacerbation compared with dapagliflozin, with no significant difference in UTI…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,466 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.